β-Amyloid (1-42) peptide deposition in the brain is one of the two hallmarks of Alzheimer’s Disease (AD), besides neurofibrillary tangles. Pathological changes in the β-Amyloid metabolism are the earliest alterations during AD development. These changes are reflected by the decrease in the CSF concentrations of β-Amyloid (1-42) as well as by the increase in the brain uptake of the specific tracers on the β-Amyloid PET.1
Elecsys® β-Amyloid(1-42) CSF II (AB42 2) is an in vitro diagnostic immunoassay intended for the quantitative determination of the β-Amyloid(1-42) protein concentration in human cerebrospinal fluid (CSF).2
Elecsys® AB42 2 assay is part of the Elecsys® AD portfolio, along with Elecsys® Phospho-Tau (181P) CSF (pTau) and Elecsys® Total-Tau CSF (tTau) immunoassays.2
Elecsys® AD CSF assays can detect amyloid positivity, enhancing diagnostic accuracy and physician confidence.3,4
Elecsys® AD CSF assays enable timely intervention by identifying patients with MCI at risk of progression to AD.2,4
